161 related articles for article (PubMed ID: 38544922)
1. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study.
Adami G; Pedrollo E; Rossini M; Fassio A; Braga V; Pasetto E; Pollastri F; Benini C; Viapiana O; Gatti D
JBMR Plus; 2024 Apr; 8(4):ziae016. PubMed ID: 38544922
[TBL] [Abstract][Full Text] [Related]
2. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.
Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
Bone; 2022 Sep; 162():116480. PubMed ID: 35787482
[TBL] [Abstract][Full Text] [Related]
3. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
McClung MR; Brown JP; Diez-Perez A; Resch H; Caminis J; Meisner P; Bolognese MA; Goemaere S; Bone HG; Zanchetta JR; Maddox J; Bray S; Grauer A
J Bone Miner Res; 2018 Aug; 33(8):1397-1406. PubMed ID: 29694685
[TBL] [Abstract][Full Text] [Related]
4. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
5. Skeletal responses to romosozumab after 12 months of denosumab.
McClung MR; Bolognese MA; Brown JP; Reginster JY; Langdahl BL; Shi Y; Timoshanko J; Libanati C; Chines A; Oates MK
JBMR Plus; 2021 Jul; 5(7):e10512. PubMed ID: 34258507
[TBL] [Abstract][Full Text] [Related]
6. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
[TBL] [Abstract][Full Text] [Related]
7. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
8. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.
Miyauchi A; Hamaya E; Shimauchi J; Yoshinaga Y; Nishi K
J Bone Miner Metab; 2024 Jan; 42(1):77-89. PubMed ID: 38086988
[TBL] [Abstract][Full Text] [Related]
11. A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.
Kumar S; Gild ML; McDonald MM; Kim AS; Clifton-Bligh RJ; Girgis CM
Osteoporos Int; 2024 Jun; ():. PubMed ID: 38839655
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.
Hu M; Zhang Y; Guo J; Guo C; Yang X; Ma X; Xu H; Xiang S
Front Endocrinol (Lausanne); 2023; 14():1188969. PubMed ID: 37529613
[TBL] [Abstract][Full Text] [Related]
13. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis.
Hong N; Shin S; Lee S; Rhee Y
Osteoporos Int; 2023 Dec; 34(12):2059-2067. PubMed ID: 37596432
[TBL] [Abstract][Full Text] [Related]
14. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study.
Mochizuki T; Yano K; Ikari K; Hiroshima R; Okazaki K
Mod Rheumatol; 2023 Apr; 33(3):490-495. PubMed ID: 35689558
[TBL] [Abstract][Full Text] [Related]
15. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration.
Kobayakawa T; Miyazaki A; Kanayama Y; Hirano Y; Takahashi J; Suzuki T; Nakamura Y
Mod Rheumatol; 2023 Jan; 33(1):96-103. PubMed ID: 35234889
[TBL] [Abstract][Full Text] [Related]
16. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
Cosman F; Crittenden DB; Ferrari S; Khan A; Lane NE; Lippuner K; Matsumoto T; Milmont CE; Libanati C; Grauer A
J Bone Miner Res; 2018 Jul; 33(7):1219-1226. PubMed ID: 29573473
[TBL] [Abstract][Full Text] [Related]
17. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
[TBL] [Abstract][Full Text] [Related]
18. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.
Miyauchi A; Hamaya E; Yang W; Nishi K; Libanati C; Tolman C; Shimauchi J
J Bone Miner Metab; 2021 Mar; 39(2):278-288. PubMed ID: 33057807
[TBL] [Abstract][Full Text] [Related]
19. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
[TBL] [Abstract][Full Text] [Related]
20. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study.
Kobayakawa T; Suzuki T; Nakano M; Saito M; Miyazaki A; Takahashi J; Nakamura Y
Bone Rep; 2021 Jun; 14():101068. PubMed ID: 33981812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]